Werewolf Therapeutics, Inc. (HOWL)

6.02 -0.22 (-3.53%) At close: 04:00PM EDT

Werewolf Therapeutics, Inc.

200 Talcott Ave
2nd Floor
Watertown, MA 02472
United States
(617) 952-0555
https://werewolftx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 47

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Daniel J. Hicklin Ph.D.	Founder, CEO, President, Secretary & Director	928.26k	N/A	1964
Mr. Timothy W. Trost CPA	CFO, Treasurer & Assistant Secretary	662.99k	N/A	1958
Dr. Randi Isaacs M.D.	Chief Medical Officer	702.43k	N/A	1956
Dr. Chulani Karunatilake Ph.D.	Chief Technology Officer	343.43k	N/A	1960
Ms. Ellen A. Lubman M.B.A.	Chief Business Officer	N/A	N/A	1976

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Werewolf Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.